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Objective – Lifestyle is considered a major determinant of risk of type 2 diabetes (T2D). We 3 
investigated whether daily physical activity (DPA) is associated with beta-cell function (BF) 4 
and/or insulin sensitivity (IS) in patients with T2D at the time of diagnosis.  5 
Methods – In 41 subjects enrolled in the Verona Newly-Diagnosed Type 2 Diabetes Study 6 
we assessed: (1) IS, by euglycaemic insulin clamp; (2) BF, estimated by prolonged-OGTT 7 
minimal modeling and expressed as derivative and proportional control; (3) DPA and energy 8 
expenditure (EE), assessed over 48-hours monitoring by a validated wearable armband 9 
system.  10 
Results – Study participants (median[IQR]; age: 62 [53-67] years, BMI: 30.8 [26.5-34.3] 11 
Kg⋅m-2, HbA1c: 6.7 [6.3-7.3]%; 49.7 [45.4-56.3] mmol/mol) were moderately active 12 
(footsteps/day: 7,773 [5,748-10,927]; DPA≥3MET: 70 [38-125] min/day), but none of them 13 
exercised above 6 metabolic equivalents (MET). EE, expressed as EETOT (total daily-EE) 14 
and EE≥3MET (EE due to DPA≥3MET) were 2,398 [2,226-2,801] and 364 [238-617] Kcal/day, 15 
respectively. IS (M-clamp 630 [371-878] µmol/min/m2) was positively associated with DPA 16 
and EE, independent of age, sex and BMI (p<0.05). Among the DPA and EE parameters 17 
assessed, DPA≥3MET and EETOT were independent predictors of IS in multivariable regression 18 
analyses, adjusted for age, sex, BMI (R2=16%, R2=19%, respectively; p<0.01). None of 19 
model-derived components of BF was significantly associated with DPA or accompanying 20 
EE.  21 
Conclusions – Our study highlighted moderate levels of DPA and total EE as potential 22 
determinants of IS, but not BF, in T2D at the time of diagnosis. Intervention studies are 23 
needed to conclusively elucidate the effect of DPA on these features. 24 
 25 
Clinical Trial Registration  – URL: http://www.clinicaltrials.gov; Unique Identifier:  26 
NCT01526720 27 
Keywords 28 















T2D = type 2 diabetes 2 
VNDS = the Verona Newly-Diagnosed Type 2 Diabetes Study 3 
IS = insulin sensitivity 4 
BF = beta-cell function 5 
OGTT = oral glucose tolerance test 6 
EE = energy expenditure 7 
DPA = daily physical activity 8 
MET = metabolic equivalent 9 
DPA≥3MET = physical activity ≥3 MET 10 
EETOT = total daily energy expenditure 11 
EE≥3MET = energy expenditure due to DPA≥3MET 12 
BMI = body mass index 13 
BSA = body surface area 14 
GAD-antibodies = Glutamic Acid Decarboxylase Autoantibodies 15 
ISR = insulin secretion rate 16 
DC = derivative control of beta-cell function 17 
PC = proportional control of beta-cell function 18 
















Type 2 diabetes (T2D) is characterized by a combination of defective beta-cell function (BF) 2 
and impaired insulin sensitivity (IS) [1], and frequently occurs as a consequence of 3 
sedentary lifestyle and “westernized” dietary habits [2, 3]. Alarming global projections for 4 
diabetes and obesity epidemics claim prompt multidisciplinary interventions and better 5 
prevention strategies to effectively target the complexity of T2D landscape [4]. Among the 6 
therapeutic lifestyle changes, a general increase in daily physical activity (DPA) is 7 
considered of pivotal relevance among the recommended interventions of current structured 8 
programs for diabetes prevention and care [5, 6]. However, notwithstanding the large 9 
evidence provided by the Diabetes Prevention Program (DPP) and other trials [7, 8] 10 
supporting the benefits of higher DPA on T2D risk, the relationship between DPA during 11 
free-living conditions and the pathophysiologic determinants of T2D (i.e. defective BF and 12 
impaired IS) at the time of disease diagnosis is still imperfectly known.  13 
 14 
Recently, Solomon et al. reported a linear association between lower IS and poorer 15 
cardiorespiratory fitness, a measure of physical activity, evaluated by gold-standard 16 
incremental stress test across the entire spectrum of glucose tolerance [9]. The authors also 17 
showed a positive relationship between cardiorespiratory fitness and the disposition index, a 18 
measure of insulin secretory compensation accounting for changing in IS. Interestingly, with 19 
regard to insulin secretion alone, considered irrespectively of extant IS, the authors identified 20 
a robust and negative association of cardiorespiratory fitness with both early and late phase 21 
of insulin secretion during an oral glucose tolerance test (OGTT) in individuals with normal 22 
and impaired glucose tolerance [9]. However, the association was considerably weaker 23 
(early phase: r=-0.23, p<0.05) or absent (second phase) in T2D patients. This might reflect 24 
the peculiar effect of exercise on the pathophysiologic determinants of T2D once the disease 25 
has established, and, as such, it warrants further investigation. 26 
Additionally, while there is a relatively large evidence supporting the beneficial effects of 27 














only a limited number of studies have reported on the physical activity of T2D patients during 1 
free-living conditions using objective measures [14, 15], and no literature is available in 2 
patients with newly-diagnosed T2D. Indeed, while accumulating evidence shows that 3 
intensive exercise training improves both BF and IS [16], there are only scanty data on the 4 
effect of moderate levels of physical activity on these aspects [17].  5 
 6 
Therefore, in the present study we explored the amount of free-living DPA and 7 
accompanying energy expenditure (EE), assessed by a wearable motion sensor, in a 8 
sample of drug-naïve patients with newly-diagnosed T2D enrolled in the Verona Newly 9 
Diagnosed Type 2 Diabetes Study (VNDS). In particular, we investigated the association of 10 
















RESEARCH DESIGN AND METHODS  1 
Study population  2 
The Verona Newly Diagnosed Type 2 Diabetes Study (VNDS) is an ongoing research 3 
project, aimed at building a bio-bank of patients of Italian ancestry with GAD-antibodies 4 
negative (GAD65 <1 KU/L), drug-naïve, newly-diagnosed diabetes. A detailed description of 5 
the study protocol has been specified elsewhere [18] and is also available in the 6 
Supplementary Material . The registered study protocol is available online at 7 
https://clinicaltrials.gov (ClinicalTrials.gov Identifier: NCT01526720). 8 
 9 
A standardized medical interview was conducted in each individual, alongside with a 10 
detailed physical examination, screening for chronic complications, assessment of body 11 
composition (% fat mass) by electrical bioimpedance (Tanita SC 330P, Tanita Corporation of 12 
America, Inc, Arlington Heights, 60005 IL, USA) and laboratory measurements, including 13 
those detailed in Table I . All study participants were tested on two separate days and in 14 
random order with a 75-grams prolonged (5-hours) oral glucose tolerance test (OGTT) to 15 
assess beta-cell function (BF), and with a hyperinsulinemic euglycaemic clamp to assess 16 
insulin sensitivity (IS), as detailed below. The study participants were drug-naïve or, if 17 
already treated with antidiabetic drugs, underwent a treatment washout of at least one week 18 
before performing metabolic tests. All subjects consumed a weight-maintaining diet 19 
containing 200-250 g of carbohydrate/day for at least three days before studies and no 20 
subject participated in any heavy exercise. Body weight was stable in all subjects for at least 21 
1 month before metabolic tests. The project is also backbone for ad hoc ancillary sub-22 
projects or pilot studies according to scientific questions to be specifically addressed. In this 23 
paper we report data on daily physical activity (DPA) and accompanying energy expenditure 24 
(EE) recorded in 41 random VNDS participants during 48 hours of free-living conditions 25 
within the first week after the metabolic tests. The anthropometric, clinical and metabolic 26 














exercised above 6 METs; therefore, only data of EE and DPA pertaining to light-to-moderate 1 
exercise levels are presented and discussed here. 2 
The VNDS study protocol was approved by the local Institutional Review Board, and all 3 
subjects gave written informed consent upon recruitment. 4 
 5 
Standard biochemistry  6 
Plasma glucose concentration was measured in duplicate with a Beckman Glucose Analyzer 7 
II (Beckman Instruments, Fullerton, CA, USA) or an YSI 2300 Stat Plus Glucose&Lactate 8 
Analyzer (YSI Inc., Yellow Springs, OH, USA), at bedside. Serum C-peptide and insulin 9 
concentrations were measured by chemiluminescence [19]. Glycosylated hemoglobin 10 
(HbA1c) was measured by a high-performance liquid chromatography analyzer on Tosoh G7 11 
automated analyzer (Tosoh Bioscience Inc., San Francisco, CA; USA); the upper limit of 12 
normal for our laboratory was 5.6% (38 mmol/mol). Serum lipids were assessed by standard 13 
in-house methods. GAD-antibodies were measured by immunoradiometry (CentAK, 14 
Medipan, Germany), according to manufacturer's instructions.   15 
 16 
Assessment of beta-cell function 17 
The analysis of the glucose and C-peptide time courses during OGTT was performed by 18 
mathematical modeling as previously described [18]. The insulin secretion rate (ISR) was 19 
modeled as comprised by two components, one being function of the rate of glucose 20 
increase and the other dependent on glucose concentration per se. Model estimates of both 21 
ISR components were normalized by body surface area (BSA) and were calculated to obtain 22 
two main physiological outputs, as follows:  23 
1. Derivative control (DC) of BF, expressed as the amount of insulin secreted in 24 
response to a rate of glucose increase of 1 mmol/L/min, which lasts for 1 min [ISR, 25 
(pmol/m2BSA) (mmol/L/min)
-1]; 26 
2. Proportional control (PC) of BF, representing the stimulus-response curve linking 27 














at preselected glucose concentrations of 5.5, 8.0, 11.0, 15.0 and 20.0 mmol/L.  1 
Further modeling details are available in the Supplementary Material . 2 
 3 
Assessment of insulin sensitivity  4 
On a separate day, as detailed in the Supplementary Material  and in prior publications [20-5 
22], the individual insulin sensitivity (IS) of each study participant was assessed by applying 6 
the gold-standard technique of the hyperinsulinemic euglycaemic clamp [23, 24], and it was 7 
expressed as the amount of glucose metabolized during the last 60 min of the clamp.  8 
 9 
Assessment of physical activity and energy expenditure  10 
Individual data on physical activity and energy expenditure were recorded over 48 hours 11 
monitoring and expressed as a daily average. Physical activity was classified according to 12 
the corresponding energy cost (also dubbed as MET, metabolic equivalent, according to the 13 
definition of Jetté et al. [25]) as light (<3 METs), moderate (3≤ METs <6) or intense (≥6 14 
METs) and it was either expressed as the number of footsteps per day or as exercise 15 
duration (minutes per day) in each MET category. 16 
Daily physical activity (DPA), total daily energy expenditure (EETOT, kilocalories per day) and 17 
energy expenditure due to DPA ≥3 MET (EE≥3MET) were measured by the SenseWear
® 18 
Armband (SWA, Body Media Inc, Pittsburgh, PA).  19 
The SWA is a wearable armband inertial sensor previously validated as effective and 20 
reliable instrument to assess free-living physical activity and EE [26, 27]. The device is 21 
comprised of a built-in two-axis accelerometer, a heatflux and skin temperature sensor, a 22 
galvanic skin response sensor, and a near-body ambient temperature sensor to obtain 23 
individual data. The SWA was randomly offered to patients upon enrollment in the VNDS 24 
study. It was positioned over the triceps muscle on the upper right arm and kept in place for 25 
two consecutive days. All participants were instructed to remove the armband only for 26 















Statistical Analysis  1 
Data are presented as means ±SD or median and interquartile range [IQR], unless 2 
otherwise indicated. Before comparisons, skewed variables were natural log-transformed to 3 
correct for non-Gaussian distributions. Unpaired Student’s t test or chi-square test was 4 
applied for continuous or categorical variables, respectively, to test for sex-related 5 
differences in the clinical, anthropometric or metabolic characteristics among the study 6 
participants. The bivariate association (expressed as Pearson’s correlation coefficient, with 7 
significance set at two-tailed p-value <0.05) of physical activity measures with body 8 
composition and metabolic parameters was explored first in the whole sample and thereafter 9 
separately in men and women. One-way ANOVA, adjusted for age, sex and body-mass 10 
index (BMI), was carried out to explore the distribution of insulin sensitivity across 11 
incremental categories of physical activity and energy expenditure measures, calculated as 12 
tertiles of the daily number of footsteps, DPA≥3MET, EETOT and EE≥3MET. The same analyses 13 
were applied to women and men, respectively. 14 
Generalized linear regression models (GLM) were applied to evaluate the contribution to IS 15 
variance (dependent variable) carried by the daily number of footsteps (Model M1), 16 
DPA≥3MET (Model M2), EETOT (Model M3) or EE≥3MET (Model M4), independent of age, sex 17 
and BMI. The same analyses were conducted by replacing BMI with waist circumference. 18 
The covariates included in the multivariable regression analyses were chosen as potential 19 
confounding factors on the basis of their significance in univariate analysis or on their 20 
biological plausibility. A stepwise-forward linear regression model including footsteps/day, 21 
DPA≥3MET, EE≥3MET, EETOT, age, sex, BMI and waist as potential predictors of IS was applied 22 
to account for possible collinearity issues. All statistical analyses were carried out with SPSS 23 
22.0 software. Type I error rate was set at two-tailed p<0.05. 24 
 25 
RESULTS 26 
As shown in Table I , the study sample was mainly comprised of middle-aged, overweight 27 














none of them was on oral hypoglycemic agents or on insulin therapy, while 24.3, 60.9 and 1 
24.4% was on lipid-lowering, anti-hypertensive and/or aspirin medication, respectively. The 2 
duration of DPA≥3MET and daily EE (either total or ≥ 3 METs) were higher in males. No further 3 
sex differences were found in the other parameters assessed. 4 
In bivariate analysis, DPA (footsteps and DPA≥3MET) and EE (EETOT and EE≥3MET) were 5 
associated with several body composition measures and metabolic parameters, but not with 6 
model-derived BF metrics (Table II  and Supplementary Figures S1, S2, S5-S9 ). In 7 
particular, both footsteps and DPA≥3MET showed a significant, inverse association with BMI, 8 
waist circumference, and triglyceride levels, while bioimpendance-assessed fat-mass was 9 
inversely associated with DPA≥3MET only. Higher levels of DPA≥3MET, EE≥3MET and incremental 10 
footsteps/day were also significantly associated with higher HDL-cholesterol levels and 11 
higher clamp-assessed IS, particularly in men.  12 
As shown in Figure 1 , when IS was considered as a categorical variable and expressed as 13 
tertiles of M-clamp, the distribution of DPA≥3MET, EETOT, EE≥3MET and footsteps across 14 
incremental categories of IS was robust against correction for age, sex and BMI (one-way 15 
ANOVA, p<0.05, Figure 1 ). Similar results were also obtained by replacement of BMI with 16 
either waist or bioimpedance-assessed fat-mass (data not shown). Separate analyses by 17 
sex (Figure S3 -S4) showed similar trends in the distribution of physical activity and energy 18 
expenditure measures, although statistical significance was reached only for DPA≥3MET in 19 
men, probably due to limited statistical power. 20 
In GLMs adjusted for age, sex and BMI (model M2: R2=22%, p=0.05; model M3: R2=24%, 21 
p=0.03, Table III ), DPA≥3MET and EETOT were significantly associated with IS, each explaining 22 
16% and 19% of IS variance, respectively. Similar results were obtained in analogous GLMs 23 
(models M1, M4) for the number of footsteps/day and EE≥3MET, although both models 24 
underperformed in their overall descriptive ability of IS variance (M1: R2=18%, p=0.11; M4: 25 
R2=21%, p=0.08).  26 
In GLMs adjusted for age, sex and waist circumference (model M2: R2=24.2%, p=0.04; 27 














EE≥3MET were significantly associated with IS, each explaining 16%, 8% and 14% of IS 1 
variance, respectively. The model including the number of footsteps/day did not perform 2 
sufficiently to describe the IS variance (M1: R2=21.3%, p=0.07).  3 
Eventually, only DPA≥3MET survived as independent predictor of IS (R
2=16%, p<0.009), when 4 
entered in a stepwise-forward linear regression model also including EE≥3MET, the number of 5 
















In this analysis, conducted in a random subset of adults with newly-diagnosed T2D 2 
participating in the VNDS Study, we observed that: 1) higher levels of free-living DPA and 3 
accompanying EE were consistently associated with several body composition measures 4 
and metabolic parameters in the expected effect direction (namely, higher IS, lower adiposity 5 
measures and a more favorable lipid profile); 2) the positive association of IS with 6 
incremental DPA and EE was robust against correction for age, sex and adiposity measures; 7 
3) among the DPA and EE parameters assessed, DPA≥3MET, EETOT and EE≥3MET individually 8 
resulted as significant predictors of IS independently of age, sex and adiposity measures; 4) 9 
only DPA≥3MET eventually survived as independent predictor of IS variance in a 10 
comprehensive stepwise-forward linear regression model also including EE≥3MET, the number 11 
of footsteps/day, EETOT, age, sex, BMI and waist); 5) DPA and EE were not significantly 12 
associated with the model-derived measures of BF. 13 
 14 
Our findings represent, to our knowledge, the first report of DPA and accompanying EE in 15 
patients with newly-diagnosed T2D. They are in line with previous observations regarding 16 
the association of moderate-to-vigorous physical activity with a more favorable cardio-17 
metabolic profile in both T2D patients [15] and in adult individuals from the general 18 
population [28]. Interestingly, we herein reported the first evidence of a strong and positive 19 
association of incremental levels of DPA and EE with whole-body IS in free-living conditions, 20 
by assessing BF and IS with state-of-the-art techniques.  21 
The underlying mechanisms as to why DPA, EE and footsteps may be associated with IS 22 
could not be explored in detail in the present study, as we did not employ tracers or 23 
hormonal assays to dissect the complex interplay between IS and BF by quantitatively 24 
estimating the changes of hepatic gluconeogenesis and the glucose uptake by the skeletal 25 
muscle and the adipose tissue. We rather identified DPA≥3MET as the principal and 26 
independent determinant of IS by a multiple-step regression approach, which allowed to 27 














energy expenditure assessed by the armband system. The separate analyses conducted to 1 
clarify the predictors of IS according to different measures of adiposity revealed a better 2 
performance of waist circumference, as compared to BMI, at improving the overall 3 
descriptive ability of the regression models. This points to the relevance of fat distribution, 4 
rather than general adiposity, in the overall economy of body energy balance. Of note, the 5 
association with higher IS was limited to DPA≥3MET, while the number of footsteps/day (which 6 
could be considered a reasonable proxy for the total volume of DPA in our patients) did not 7 
play a significant contribution to IS. This suggests that the energy costs associated with 8 
DPA≥3MET may have a greater impact on the individual cardiometabolic profile, than those 9 
associated with the volume of DPA alone. 10 
 11 
As mentioned above, Solomon et al. have recently reported a linear association between 12 
lower IS and poorer cardiorespiratory fitness across the entire range of glucose tolerance 13 
[9], but the authors did not find conclusive results on the inverse association of 14 
cardiorespiratory fitness with the components of BF in patients with overt T2D. Our study 15 
adds further evidence against the association of DPA or EE variables with BF in patients 16 
with (newly-diagnosed) T2D. Whether physical activity is able to improve insulin secretion 17 
while reducing insulin resistance has been object of investigation for several years. 18 
However, while there is supportive evidence from some intervention studies on the efficacy 19 
of aerobic exercise training at improving BF in patients with T2D [29-31], recent results from 20 
the RAED2 study, a randomized clinical trial conducted by our group, did not reveal 21 
significant improvements of BF after random assignment to structured aerobic or resistance 22 
training in 40 patients with T2D [32]. However, the disparity in the results obtained by these 23 
studies might be explained by the different methods employed to estimate BF (surrogate 24 
indexes of BF, simple C-peptide concentrations or mathematical modeling) as well as by the 25 
different exercise protocols applied, which all hamper the head-to-head comparison. 26 
 27 














methods [33-35] to assess BF and insulin sensitivity; b) study patients with newly-diagnosed 1 
and drug-naïve T2D, thereby minimizing the effect of a long standing disease and limiting 2 
the potentially confounding effects of glucose-lowering medications; c) consecutive 3 
recruitment of patients among those attending to the VNDS; as such, the wearable armband 4 
system was offered to unselected VNDS participants without any accidental or purposely 5 
occurring influence by the enrolling physician.  6 
 7 
Our analysis, however, has a number of limitations that should be acknowledged, not 8 
ultimately the limited sample size. The SWA was available at our institution for a limited 9 
period and it was therefore possible to propose its positioning to a limited number of patients 10 
only. This was the major issue that prevented us to enroll, although desirable, a larger 11 
number of patients and thus to perform more detailed analyses. Our study, indeed, was 12 
descriptive in nature and it was not designed to explore causal relationships or to unravel 13 
mechanistic insights on the effects of increasing DPA and accompanying EE. Additionally, 14 
the absence of a control group without T2D might affect the generalizability of our findings. It 15 
is also noteworthy that, although vigorous-intense physical activity may be relevant in the 16 
relationship with clinical parameters, none of the study patients exercised above 6 METs, 17 
and it therefore remains untested whether high-intensity exercise may give extra benefits 18 
over light-to-moderate physical activity in our patient population. There are also other 19 
unmeasurable confounding elements that should be mentioned, including the fact that, 20 
although our patients did not receive specific physical activity counselling upon the study 21 
enrollment (with the only exception of refraining from heavy exercise in the days preceding 22 
the metabolic tests), the application of the SenseWear® Armband per se may have affected 23 
the DPA features in these subjects. Lastly, since the communication of a T2D diagnosis 24 
represents an important milestone in the individual life, it is possible that the increased 25 
awareness per se may have already induced diet and physical activity habits changes, with 26 















As for the novelty of our results, it is noteworthy that the benefits of moderate and 1 
unstructured physical activity on insulin sensitivity have been observed in untrained 2 
individuals and that the positive relationship with the metabolic health parameters was 3 
already evident since diabetes diagnosis. Indeed, the timing of T2D onset and its diagnosis 4 
are not necessarily overlapping, and usually the latter follows the former after several weeks 5 
or months, if not years. However, in many circumstances, the time of T2D diagnosis 6 
represents the only practicable proxy of T2D onset, and a hitherto unparalleled opportunity 7 
to detect the first instances of the disruption between IS and BF during the natural history of 8 
T2D. Additionally, it could not be excluded that long-term structured physical activity 9 
programs may eventually result in measurable improvements of BF. 10 
 11 
In conclusion, although further interventional studies are needed to definitely demonstrate 12 
whether stepwise incremental levels of moderate DPA effectively improve the individual 13 
metabolic health parameters in these patients, our data strengthen the confidence that 14 
simple recommendations to increase the time spent in moderate levels of physical activity 15 
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Includes text with supplemental information regarding methods and results, tables S1-S2 21 
and figures S1-S9. 22 
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Table I – Clinical and metabolic features of the study sample.  
 
Variables Men Women All p-value * 
N  24 17 41  
Age , years 63 [50-67] 63 [50-67] 62 [52.5-67] ns 
BMI, Kg·m-2 29.8 [26.2-32.7] 32.5 [28.1-35.3] 30.8 [26.5-34.3] ns 
Waist circumference , cm 100.5 [91-112] 99 [95-101] 99.5 [92.5-108] ns 
Fat Mass , % 33.5 [26.5-41.6] 41.3 [38.8-43.6] 39.2 [31.6-43.1] ns 
Fasting insulin ,mU/L 76.8 [34.7-108.5] 75.6 [53.4-113.7] 76.8 [45.0-104.4] ns 
Fasting plasma glucose , mmol/L 7.1 [6.1-8.9] 7.1 [6.5-8.5] 7.1 [6.4-8.8] ns 
2hr plasma glucose , mmol/L 13.5 [9.9-16.9] 13.3 [10.1-14.3] 13.3 [10.1-15.9] ns 
Glucose -AUCOGTT, mmol/L·min 163 [125-217] 139 [128-184] 155 [128-202] ns 
HbA1c-DCCT, % 6.7 [6.2-7.6] 6.9 [6.5-7.3] 6.7 [6.3-7.3] ns 
HbA1c-IFCC, mmol/mol 49.7 [44.3-59.6] 51.9 [47.5-56.3] 49.7 [45.4-56.3] ns 
Total cholesterol , mmol/L 5.1 [4.2-5.7] 5.2 [4.5-5.9] 5.1 [4.3-5.8] ns 
C-HDL, mmol/L 1.0 [0.9-1.2] 1.1 [1.0-1.3] 0.9 [1.1-1.3] ns 
Triglycerides , mmol/L 1.6 [1.0-2.1] 1.2 [1.1-1.9] 1.4 [1.1-2.0] ns 
SBP, mmHg 132 [130-149] 140 [130-150] 140 [130-150] ns 
DBP, mmHg 82 [80-90] 80 [80-90] 80 [80-90] ns 
Lipid -lowering medications , % 25 23.5 24.3 ns 
Anti -hypertensive medications , % 62.5 58.8 60.9 ns 
Aspirin , % 20.8 29.4 24.4 ns 
Smoking status , % (ever/never) 70.8 52.9 63.4 ns 
Insulin sensitivity:  
 M clamp , µmol/min/m2 BSA 505 [221-949] 644 [464-748] 630 [371-878] ns 
 HOMA-IR, score 3.8 [1.9-7.5] 3.9 [3.1-5.5] 3.9 [2.3-5.9] ns 
 Matsuda Index  3.1 [1.6-7.2] 2.5 [1.9-3.5] 2.7 [1.9-4.6] ns 
Beta-Cell Function:  
 Derivative Control  
(pmol·m−2 BSA)·(mmol·L−1·min−1)−1 
640.1 [191-1100] 94.3 [0-708] 333.8 [0.3-909] 0.06 
 Proportional Control  
(pmol·min−1·m−2 BSA) 
51.5 [32-101] 54.3 [35-85] 53.9 [33-90] ns 
 HOMA-B, % 61.8 [35.7-100.3] 58.0 [37.7-123.7] 58.0 [37.1-101.2] ns 
 Insulinogenic Index  (mU/mmol) 4.0 [2.6-8.6] 5.8 [2.6-7.6] 4.2 [2.2-7.4] ns 
 CIR120’ (mU⋅L/mmol
2) 0.6 [0.3-1.9] 0.9 [0.2-1.4] 0.6 [0.2-1.6] ns 
 Disposition Index § 23.2 [12.4-67.1] 27.1 [13.4-36.6] 24.7 [12.7-44.5] ns 
Physical activity (PA)  
 PA ≥3 METs, min/day 81.8 [59-145] 53 [32-86] 70 [38-125] 0.05 
 3< PA <6 METs, min/day 81.8 [59-145] 53 [32-86] 70 [38-125] 0.05 
 Footsteps , N of steps/day 7,718 [5479-1,1202] 8,728 [5,748-10,927] 7,773 [5,748-10,927] ns 
Energy Expenditure (EE)  
 EETOT, Cal/day 2,751 [2,402-3,065] 2,229 [2,065-2,365] 2,398 [2,226-2,801] <0.001 
 EE ≥3 METs, Cal/day 406 [282-764] 283 [162-428] 364 [238-617] <0.05 
Resting (lying) , hours/day 8.3 [7.2-9.7] 8.3 [7.3-9.4] 8.3 [7.3-9.5] ns 
Resting (sleeping) , hours/day 6.7 [5.0-7.6] 6.8 [6.2-8.2] 6.8 [5.2-7.9] ns 
 
Legend: Data are presented as median [I.Q. range]; BMI, Body Mass Index; HbA1c-DCCT, Diabetes Control and Complication Trial-
Aligned Hemoglobin A1c; HbA1c-IFCC, International Federation of Clinical Chemistry-Aligned Hemoglobin A1c; SBP, Systolic Blood 
Pressure; DBP, Diastolic Blood Pressure; HOMA-IR, Homeostasis Model Assessment of Insulin Resistance; HOMA-B, Homeostasis 
Model Assessment of Beta-cell Function; AUC, area under the curve; BSA, Body Surface Area; CIR120’, corrected insulin response at 
120’ of the OGTT; Matsuda Index: 10,000/[(Glucose0’·Insulin0’)·(mean OGTT glucose concentration)·(mean OGTT insulin 
concentration)]1/2; METs, METabolic Equivalents; EETOT, Total Daily Energy Expenditure. 
§Disposition Index was calculated according to 
the following formula: DI=(∆I0’-120’/∆G0’-120’) x Matsuda Index. *Sex differences were evaluated by unpaired two-sample t-test or chi-
square test for continuous or categorical variables, respectively. Non-Gaussian variables were natural-log transformed.  















Table II – Correlations (Pearson’s r) between physical activity measures,  body composition and metabolic parameters.  
 
Variables Footsteps 
N of steps/day 




EE ≥3 METs 
Kcal/day 
 Men Women  All  Men Women  All  Men Women  All  Males Females  All  
BMI, Kg/m2 -0.31 -0.36 -0.31* -0.28 -0.4 -0.37* 0.25 0.35 0.08 -0.2 -0.29 -0.29 
Waist Circumference , cm -0.31 -0.62* -0.42* -0.39 -0.56* -0.37* 0.24 0.26 0.27 -0.32 -0.42 -0.28 
Fat mass , % -0.14 -0.32 -0.14 -0.25 -0.33 -0.33* 0.02 0.22 -0.12 -0.22 -0.28 -0.29 
HbA1c-DCCT, % -0.05 0.16 0.04 0.09 -0.04 0.03 0.08 0.02 0.02 0.1 0.06 0.06 
Fasting Plasma Glucose , mmol/L 0.18 -0.19 0.06 0.14 -0.01 0.13 0.18 0.23 0.21 0.15 0.08 -015 
2-hour Plasma Glucose , mmol/L -0.08 0.11 -0.01 -0.11 -0.04 -0.05 0.01 0.12 0.09 -0.11 0.07 -0.01 
Glucose -AUCOGTT, mmol/L·min 0.08 0.08 0.07 -0.01 0.01 0.05 0.06 0.28 0.18 -0.01 0.14 0.09 
C-HDL, mmol/L 0.36 0.3 0.33* 0.53* 0.35 0.33* 0.39 0.15 0.10 0.51* 0.38 0.32* 
Triglycerides , mmol/L -0.49* -0.42 -0.46* -0.37 -0.4 -0.32* -0.24 0.12 -0.07 -0.37 -0.34 -0.29 
Disposition Index  0.11 0.09 0.04 0.02 0.35 0.08 -0.11 -0.32 -0.05 -0.01 0.15 0.05 
Insulin Sensitivity:              
 M clamp , µmol/min/m2 BSA 0.47* 0.55* 0.45* 0.53* 0.49 0.45* 0.38 -0.06 0.18 0.52* 0.42 0.41* 
Beta-cell Function:              
 Derivative Control   
(pmol·m−2BSA)·(mmol·L
−1·min−1)−1 
-0.32 0.3 0.05 -0.12 0.18 0.09 -0.19 0.29 0.12 -0.13 0.14 0.08 
 Proportional Control  
(pmol·min−1·m−2 BSA) 
-0.04 0.15 0.04 -0.14 0.18 -0.08 -0.16 0.19 -0.18 -0.14 0.04 -0.11 
 
*Association is significant at two-tailed p<0.05; BMI, Body Mass Index; BSA, Body Surface Area; C-HDL, High Density Lipoprotein Cholesterol; EE, Daily Energy Expenditure; HbA1c-DCCT, Diabetes Control 















Table III  – Predictors of insulin sensitivity by generalized 
linear regression models. 
 
Model 1 (R2=18%, p=0.11) Beta P adjusted -R2 
Footsteps 0.36 0.03 0.13 
Age 0.18 0.26 0.03 
Sex  -0.03 0.83 0.001 
BMI -0.05 0.75 0.03 
 
Model 2 (R2=22%, p=0.05)    
DPA ≥3 MET 0.44 0.01 0.16 
Age 0.18 0.23 0.04 
Sex  0.12 0.47 0.01 
BMI -0.04 0.80 0.002 
 
Model 3  (R2=24%, p=0.03) 
EETOT 0.52 0.006 0.19 
Age 0.21 0.17 0.05 
Sex  0.32 0.09 0.07 
BMI 0.29 0.06 0.09 
 
Model 4 (R2=21%, p=0.08) 
EE ≥3 MET 0.41 0.02 0.15 
Age 0.19 0.23 0.04 
Sex  0.12 0.45 0.02 
BMI -0.09 0.59 0.01 
 
Multivariable linear regression models (dependent variable: insulin 
sensitivity; independent variables: age, sex, BMI, footsteps (Model 1), 

















Table IV – Predictors of insulin sensitivity by generalized 
linear regression models. 
 
Model 1 (R2=21.3%, p=0.07) ßstd  P adjusted -R
2 
Footsteps 0.30 0.08 0.15 
Age 0.18 0.23 0.03 
Sex  -0.07 0.64 0.001 
Waist -0.20 0.23 0.10 
 
Model 2 (R2=24.2%, p=0.04)    
DPA ≥3 MET 0.37 0.04 0.16 
Age 0.19 0.21 0.03 
Sex  0.06 0.71 1.2*10-4 
Waist -0.17 0.30 0.10 
 
Model 3  (R2=35%, p=0.003) 
EETOT 0.56 0.002 0.08 
Age 0.24 0.09 0.03 
Sex  0.20 0.22 1.2*10-4 
Waist 0.44 0.003 0.10 
 
Model 4  (R2=24%, p=0.04) 
EE ≥3 MET 0.35 0.04 0.14 
Age 0.20 0.20 0.03 
Sex  0.05 0.74 1.2*10-4 
Waist -0.21 0.19 0.10 
 
Multivariable linear regression models (dependent variable: insulin 
sensitivity; independent variables: age, sex, waist, footsteps (Model 1), 













FIGURE LEGEND 1 
 2 
Figure 1 – Distribution of insulin sensitivity acro ss incremental categories of physical 3 
activity and energy expenditure measures in patient s with newly-diagnosed type 2 4 
diabetes.  The figure shows the significant relationship of moderate levels of physical activity 5 
and energy expenditure with increasing insulin sensitivity levels, independent of age, sex 6 
and adiposity. Categories on the x-axes of panels A, B, C and D are expressed, 7 
respectively, as tertiles of footsteps, DPA≥3MET, EETOT and EE≥3MET, and calculated from the 8 
SWA records obtained in the whole sample. Data expressed as mean±SEM. One-way 9 
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Highlights: 
• Physical activity is a major determinant of glucose homeostasis. 
• Whether free-living physical activity impacts insulin sensitivity, beta-cell function 
or both is poorly understood. 
• We tested these questions in deeply phenotyped, newly-diagnosed type 2 
diabetes. 
• Clamp-assessed insulin sensitivity was linearly associated with moderate 
physical activity, while model-derived beta-cell function was not.  
• These data highlight that moderate and unstructured physical activity shows its 
metabolic benefits in untrained individuals since diabetes diagnosis.  
• Whether structured programs of moderate physical activity may also improve 
beta-cell function warrants further investigation 
